TacticScaleWhat Stryker Does & How It Makes Money (SYK)
Updated October 2026 · reflects Stryker's latest reported financials
Medical technology company making surgical equipment, orthopedic implants and robotics. Stryker sells surgical equipment, disposables, implants and robotic systems to doctors, hospitals and other healthcare facilities.
How Stryker makes money
Stryker sells surgical equipment, disposables, implants and robotic systems to doctors, hospitals and other healthcare facilities. It sells through its own subsidiaries and branches, and through third-party dealers and distributors in about 61 countries.
What Stryker does
Stryker is a Michigan-based medical technology company founded in 1941 that reports two segments. MedSurg and Neurotechnology covers surgical equipment, navigation, endoscopic and communications systems, patient handling, emergency medical equipment, intensive-care disposables, and an AI-assisted virtual care platform. It also includes minimally invasive devices for stroke and venous thromboembolism, brain and skull-base surgery products, and orthobiologics such as synthetic bone grafts and vertebral augmentation. The Orthopaedics segment makes implants for hip, knee, shoulder and ankle replacements and for trauma and extremities surgery. Its Mako robotics platform, which now includes shoulder applications, ties implants to robot-assisted procedures. Stryker sells to doctors, hospitals and other healthcare facilities through its own subsidiaries and branches, and through dealers and distributors in about 61 countries.
Products & services
- Mako robotic surgery system (incl. Mako Shoulder)
- Hip, knee, shoulder and ankle joint replacement implants
- Trauma and extremities implants
- Surgical navigation and endoscopic systems
- Patient handling and emergency medical equipment
- Stroke treatment devices (ischemic and hemorrhagic)
What is Stryker worth?
On an owner-earnings DCF, Stryker's most-likely value is about $350 versus a recent price near $277 (26% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$139) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Zimmer Biomet (ZBH) · STERIS (STE) · Medtronic (MDT) · Globus Medical (GMED) · Boston Scientific (BSX)